Dermaveel® es una pomada que repara eficazmente la barrera cutánea para el tratamiento del eczema atópico leve a moderado. Se puede utilizar al primer signo de irritación, a saber, picor y enrojecimiento. Se tolera bien, no contiene esteroides y se puede aplicar a diario en cualquier zona afectada con piel íntegra, incluida la cara.
Dermaveel® proporciona tres modos de actuación.
Bibliografía
Dermaveel®: Resumen de las características del producto.
Wilkowska A, Grubska-Suchanek E, Nowicki R. Evaluation of safety and efficacy of Dermaveel in treatment of atopic dermatitis. Alergologia Polska, nr 4/2015.
Graf R, Anzali S, Buenger J et al. The multifunctional role of ectoine as a natural cell protectant. Clin Dermatol 2008;26:326–33.
Harishchandra RK, Wulff S, Lentzen G, et al. The effect of compatible solute ectoines on the structural organization of lipid monolayer and bilayer membranes. Biophys Chem 2010;150:37–46.
Amarowicz R, Dykes GA, Pegg RB Antibacterial activity of tannin constituents from Phaseolus vulgaris, Fagoypyrum esculentum, Corylus avellana and Juglans nigra. Fitoterapia 2008;79:217–9.
Chirumbolo S. The role of quercetin, flavonols and flavones in modulating inflammatory cell function. Inflamm Allergy Drug Targets 2010; 9:263–285.
Valdman-Grinshpoun Y, Ben-Amitai D, Zvulunov A. Barrier restoring therapies in atopic dermatitis: current approaches and future perspectives. Dermatol Res Pract. 2012;2012:923134.
Wohlrab J, Klapperstück T, Reinhardt HW, et al. Interaction of epicutaneously applied lipids with stratum corneum depends on the presence of either emulsifiers or hydrogenated phosphatidylcholine. Skin Pharmacol Physiol 2010;23:298–305.
Atopic eczema in children – management of atopic eczema in children from birth up to the age of 12 years. Clinical Guideline Commissioned by the National Institute for Health and Clinical Excellence; 2007.
Ring J et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. Aug 2012;26(8):1045-60.